Structured approach to pharmaceutical representatives: Family medicine residency program

Canadian Family Physician

Volumn 44, Issue MAY., 1998, Pages 1053-1060

  Kelcher, Sheila ^a   Brownoff, Rene ^b   Meadows, Lynn M ^b  

^a Misericordia Community Hospital   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANADA; COMMERCIAL PHENOMENA; DRUG INDUSTRY; EDUCATION; GENERAL PRACTICE; HUMAN; MEDICAL EDUCATION; PUBLIC RELATIONS;

ALBERTA; COMMERCE; DRUG INDUSTRY; FAMILY PRACTICE; HUMANS; INTERNSHIP AND RESIDENCY; INTERPROFESSIONAL RELATIONS;

EID: 0032058915     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ziegler M, Lew P, Singer B. The accuracy of drug information from pharmaceutical sales representatives. JAMA 1995; 273:1296-8.
2. Chren MM, Landefeld CS. Physicians' behavior and their interaction with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994;271:684-9.
3. Chren MM, Landefeld CS, Murray TH. Doctors, drug companies and gifts. JAMA 1989;262:3448-51.
4. Vinson D, McCandless B, Hosokawa M. Medical students' attitudes toward pharmaceutical marketing: possibilities for change. Fam Med 1993;25:31-3.
5. Avorn J, Chen M, Hartley R Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982;73:4-8.
6. Lexchin J. Interactions between physicians and the pharmaceutical industry. What does the literature say? Can Med Assoc J 1993;149:1401-7.
7. Pharmaceutical Manufacturers Association of Canada. A 5 year report on the Canadian brand name pharmaceutical industry: 1988-1993. Ottawa: Pharmaceutical Manufacturers Association of Canada; 1993.
8. Commission of Inquiry of the Pharmaceutical Industry. Tlte report of the Commission of Inquiry of the Pharmaceutical Industry. Ottawa: Pharmaceutical Manufacturers Association of Canada; 1985. p. 223.
9. Shaughnessy A, Slawson D, Bennett J. Teaching information mastery: evaluating information provided by pharmaceutical representatives. Fam Med 1995;27:581-5.
10. Anastasio G, Little J. Pharmaceutical marketing: implications for medical residency training. Pharmacotherapy 1996;16(1):103-7.
11. Shear NH, Black F, Lexchin J. Examining the physician-detailer interaction. Can J Clin Pharmacol 1996;3(4):175-9.
12. Brotzman G, Mark D. Policies regulating the activities of pharmaceutical representatives in residency programs. J Fam Pract 1992;34(1):54-7.
13. Brotzman G, Mark D. Policy recommendations for pharmaceutical representative-resident interactions. Fam Med 1992;24:431-2.
14. Education Council, Residency Training Programme in Internal Medicine, Department of Medicine, McMaster University. Development of residency program guidelines for interaction with the pharmaceutical industry. Can Med Assoc J 1993;149:405-8.
15. Canadian Medical Association. Policy summary. Physicians and the pharmaceutical industry (update 1994). Can Med Assoc J 1994;150:256A-C.
16. Sergeant M, Hodgetts PG, Godwin M, Walker D, McHenry P. Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario. Can Med Assoc J 1996;155:1243-7.
17. Guyatt G. Academic medicine and the pharmaceutical industry: a cautionary tale. Can Med Assoc J 1994;150:951-3.
18. Lurie N, Rich EC, Simpson DE, Meyer J, Schiedermayer DL, Goodman JL, et al. Pharmaceutical representatives in academic medical centres: interaction with faculty and housestaff. J Gen Intern Med 1990;5:240-3.
19. Toth E, McAllister F. Medical education and the pharmaceutical industry. Position of the Department of Medicine, University of Alberta, with special reference to the residency training program. Bioethics Bull 1995;7(1):4-5.
20. Pharmaceutical Manufacturers Association of Canada. Code of marketing practices. Ottawa: Pharmaceutical Manufacturers Association of Canada; 1993.
21. Pharmaceutical Advertising Advisory Board. Code of advertising acceptance. Pickering, Ont: Pharmaceutical Advertising Advisory Board; 1993.
22. Council for the Accreditation of Pharmaceutical Manufacturers Representatives of Canada. The blue badge of professionalism. St Laurent, Que: Council for the Accreditation of Pharmaceutical Manufacturers Representatives of Canada.